Evidence map›Paper›PMID 24020450›Full record

Trial reportBMC public health2013

Extended interactive voice response telephony (IVR) for relapse prevention after smoking cessation using varenicline and IVR: a pilot study.

Bonnie McNaughton, Jiri Frohlich, Amy Graham, Quincy-Robyn Young

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC public health, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00832806 (Smoking Cessation With Varenicline), which is not on this map. Cited by 9 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00832806 phase1completednot on this map

Smoking Cessation With Varenicline (Champix) and Integrated Voice Response Technology (IVR)

TypeinterventionalSponsorUniversity of British ColumbiaRan2008 to 2011Enrolled100ConditionsAdditional, Effective Methods to Stop SmokingArmsExtended IVR (integrated voice response technology), Varenicline (Champix), IVR treatment
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Relapse prevention interventions for smoking cessation.The Cochrane database of systematic reviews · 2019
    Pooled it
  4. Relapse prevention interventions for smoking cessation.The Cochrane database of systematic reviews · 2019
    Pooled it
  5. Pooled it
  6. Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2016
    Pooled it
  7. Trial
  8. Trial
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bonnie McNaughtonHealthy Heart Program, Providence Health Care, St, Paul's Hospital, 1081 Burrard Street, Vancouver B,C, V6Z 1Y6, Canada. bmcnaughton@providencehealth.bc.ca.
Jiri Frohlich
Amy Graham
Quincy-Robyn Young

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is a significant resumption of smoking following smoking cessation using varenicline. Both smoking cessation medications and counseling have been shown to increase smoking quit rates at one year. Thus, the combination of varenicline and interactive voice response (IVR) telephony followed by extended IVR may further improve smoking cessation rates at one and two years.

methods101 participants were recruited from the community via newspaper advertisement. They attended a group counseling session and were given smoking information booklets from the Canadian Cancer Society. After 12 weeks of varenicline and 9 IVR calls, all participants who had quit smoking were randomized into 2 groups matched by levels of motivation and addiction as per baseline questionnaire score. The intervention group continued to receive bi-weekly IVR support for weeks 13-52. The control group no longer received IVR. The primary end-point was self-reported abstinence and exhaled carbon monoxide levels of less than 10 ppm for weeks 12, 52 and 2 years. Data were analyzed by Fisher's exact test or Wilcoxon rank-sum test.

resultsOf the 101 participants, 44 (43%) had stopped smoking after 12 weeks of varenicline and 9 IVR calls. Of these, 23 (52%) were randomized to receive IVR calls from weeks 13 to 52.At 52 weeks, 26 (59%) participants remained smoke-free. Of the 23 with IVR, 12 (52.2%) stopped smoking compared to 14 of 21 (66.7%) without IVR. At 2 years, 40 of the 44 (90.9%) randomized participants were contacted and 24 of the 44 (54.5%) came in for testing. Fourteen (13% of the original cohort, 30% who were abstinent at 12 weeks and 53% who were abstinent at 52 weeks) remained smoke-free. Five of the 23 (21.7%) randomized to IVR and 9 of the 21 (42.9%) randomized to no IVR remained smoke-free at 2 years.

conclusionsIn this pilot study of an apparently healthy population, extended IVR did not affect abstinence rates. There was no relapse prevention benefit in offering 9 months of continued IVR to subjects who had stopped smoking after receiving 3 months of varenicline and IVR treatment.

trial registrationClinicalTrial.gov: NCT00832806.

Indexed as

AdultBenzazepinesCanadaDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHumansMaleMiddle AgedNicotinic AgonistsPilot ProjectsPredictive Value of TestsQuinoxalinesReminder SystemsRisk AssessmentBenzazepinesNicotinic AgonistsQuinoxalinesVarenicline

Identifiers

PMID24020450
PMCPMC3848019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.